Progress of delivery methods for CRISPR-Cas9

Wu Yang, Jiaqi Yan, Pengzhen Zhuang, Tao Ding, Yu Chen, Yu Zhang, Hongbo Zhang*, Wenguo Cui

*Tämän työn vastaava kirjoittaja

Tutkimustuotos: LehtiartikkeliKatsausartikkelivertaisarvioitu

10 Sitaatiot (Scopus)


Introduction: Gene therapy is becoming increasingly common in clinical practice, giving hope for the correction of a wide range of human diseases and defects. The CRISPR/Cas9 system, consisting of the Cas9 nuclease and single-guide RNA (sgRNA), has revolutionized the field of gene editing. However, efficiently delivering the CRISPR-Cas9 to the target organ or cell remains a significant challenge. In recent years, with rapid advances in nanoscience, materials science, and medicine, researchers have developed various technologies that can deliver CRISPR-Cas9 in different forms for in vitro and in vivo gene editing. Here, we review the development of the CRISPR-Cas9 and describe the delivery forms and the vectors that have emerged in CRISPR-Cas9 delivery, summarizing the key barriers and the promising strategies that vectors currently face in delivering the CRISPR-Cas9. Areas covered: With the rapid development of CRISPR-Cas9, delivery methods are becoming increasingly important in the in vivo delivery of CRISPR-Cas9. Expert opinion: CRISPR-Cas9 is becoming increasingly common in clinical trials. However, the complex nuclease and protease environment is a tremendous challenge for in vivo clinical applications. Therefore, the development of delivery methods is highly likely to take the application of CRISPR-Cas9 technology to another level.

JulkaisuExpert Opinion on Drug Delivery
DOI - pysyväislinkit
TilaJulkaistu - 17 heinäk. 2022
OKM-julkaisutyyppiA2 Arvio tiedejulkaisuussa (artikkeli)


Sukella tutkimusaiheisiin 'Progress of delivery methods for CRISPR-Cas9'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.